Eculizumab-induced reversal of dialysis-dependent kidney failure from C3 glomerulonephritis

Clinical Kidney Journal

Volumn 8, Issue 4, 2015, Pages 445-448

  Inman, Melissa ^a   Prater, Ginnie ^a   Fatima, Huma ^b   Wallace, Eric ^a  

^a University of Alabama at Birmingham   (United States)

^b University of Alabama at Birmingham   (United States)

Author keywords

Alternative pathway; C3 glomerulopathy; Complement; Eculizumab; End stage renal disease

Indexed keywords

ANTINUCLEAR ANTIBODY; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; COMPLEMENT MEMBRANE ATTACK COMPLEX; CREATININE; CRYOGLOBULIN; ECULIZUMAB; HEMOGLOBIN; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS C ANTIBODY; METHYLPREDNISOLONE; NEUTROPHIL CYTOPLASMIC ANTIBODY; PREDNISONE;

ADULT; ARTICLE; CASE REPORT; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DRUG EFFICACY; EDEMA; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEMODIALYSIS; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN TISSUE; KIDNEY BIOPSY; KIDNEY FUNCTION; LIGHT CHAIN; NON INSULIN DEPENDENT DIABETES MELLITUS; PERITONEAL DIALYSIS; PRIORITY JOURNAL; PROTEIN URINE LEVEL; PROTEINURIA; RAPIDLY PROGRESSIVE GLOMERULONEPHRITIS; RENAL REPLACEMENT THERAPY-DEPENDENT RENAL DISEASE; UREA NITROGEN BLOOD LEVEL;

EID: 84942087191     PISSN: 20488505     EISSN: 20488513     Source Type: Journal    
DOI: 10.1093/ckj/sfv044     Document Type: Article

References (25)

1. Sethi S, Fervenza FC, Zhang Y et al. Proliferative glomerulonephritis secondary to dysfunction of the alternative pathway of complement. Clin J Am Soc Nephrol2011; 6: 1009-1017
2. Pickering M, Cook HT. Complement and glomerular disease: New insights. Curr Opin Nephrol Hypertens 2011; 20: 271-277
3. Sethi S, Fervenza FC. Pathology of renal diseases associated with dysfunction of the alternative pathway of complement: C3 glomerulopathy and atypical hemolytic uremic syndrome (aHUS). Semin Thromb Hemost 2014; 40: 416-421
4. Fakhouri F, Frémeaux-Bacchi V, Noël L-H et al. C3 glomerulopathy: A new classification. Nat Rev Nephrol 2010; 6: 494-499
5. Servais A, Noël L-H, Frémeaux-Bacchi V et al. C3 glomerulopathy. Contrib Nephrol 2013; 181: 185-193
6. Smith RJH, Alexander J, Barlow PN et al. New approaches to the treatment of dense deposit disease. J Am Soc Nephrol 2007; 18: 2447-2456
7. Lu D-F, Moon M, Lanning LD et al. Clinical features and outcomes of 98 children and adults with dense deposit disease. Pediatr Nephrol 2012; 27: 773-781
8. Zand L, Lorenz EC, Cosio FG et al. Clinical findings, pathology, and outcomes of C3GN after kidney transplantation. J Am Soc Nephrol2014; 25: 1110-1117
9. Medjeral-Thomas NR, O'Shaughnessy MM, O'Regan JA et al. C3 glomerulopathy: Clinicopathologic features and predictors of outcome. Clin J Am Soc Nephrol2014; 9: 46-53
10. Nasr SH, Valeri AM, Appel GB et al. Dense deposit disease: Clinicopathologic study of 32 pediatric and adult patients. Clin J Am Soc Nephrol 2009; 4: 22-32
11. Nester CM, Smith RJ. Treatment options for C3 glomerulopathy. Curr Opin Nephrol Hypertens 2013; 22: 231-237
12. Legendre CM, Licht C, Loirat C. Eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med 2013; 369: 1379-1380
13. Hillmen P, Young NS, Schubert J et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med 2006; 355: 1233-1243
14. Bomback AS, Smith RJ, Barile GR et al. Eculizumab for dense deposit disease and C3 glomerulonephritis. Clin J Am Soc Nephrol 2012; 7: 748-756
15. Abrera-Abeleda MA, Nishimura C, Frees K et al. Allelic variants of complement genes associated with dense deposit disease. J Am Soc Nephrol 2011; 22: 1551-1559
16. Kurtz KA, Schlueter AJ. Management of membranoproliferative glomerulonephritis type II with plasmapheresis. J Clin Apheresis 2002; 17: 135-137
17. Habbig S, Mihatsch MJ, Heinen S et al. C3 deposition glomerulopathy due to a functional factor H defect. Kidney Int 2009; 75: 1230-1234
18. Barbour TD, Pickering MC, Cook HT. Recent insights into C3 glomerulopathy. Nephrol Dial Transplant2013; 28: 1685-1693
19. Appel GB, Appel AS. New diagnostic tests and new therapies for glomerular diseases. Blood Purif 2013; 35: 81-85
20. Pickering MC, D'Agati VD, Nester CM et al. C3 glomerulopathy: Consensus report. Kidney Int 2013; 84: 1079-1089
21. Sakari Jokiranta T, Solomon A, Pangburn M et al. Nephritogenic lambda light chain dimer: A unique human miniautoantibody against complement factor H. J Immunol 1999; 163: 4590-4596
22. Radhakrishnan S, Lunn A, KirschfinkMet al. Eculizumab and refractory membranoproliferative glomerulonephritis. N Engl J Med 2012; 366: 1165-1166
23. Vivarelli M, Pasini A, Emma F. Eculizumab for the treatment of dense-deposit disease. N Engl J Med 2012; 366: 1163-1165
24. Gurkan S, Fyfe B, Weiss L et al. Eculizumab and recurrent C3 glomerulonephritis. Pediatr Nephrol Berl Ger 2013; 28: 1975-1981
25. Noris M, Galbusera M, Gastoldi S et al. Dynamics of complement activation in atypical HUS and how to monitor eculizumab therapy. Blood 2014; 124: 1715-1726